Medicus Pharma (STU:N460) Short-Term Debt : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Medicus Pharma Short-Term Debt?

Medicus Pharma's Short-Term Debt for the quarter that ended in Dec. 2024 was €0.00 Mil.

Medicus Pharma's annual Short-Term Debt declined from Dec. 2022 (€1.45 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Medicus Pharma Short-Term Debt Historical Data

The historical data trend for Medicus Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Short-Term Debt Chart

Medicus Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

0.59

1.45

Medicus Pharma Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial								-	-	-	-	-

Medicus Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Medicus Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Medicus Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicus Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (STU:N460) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

MDCX:USA

Address

100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4

Website

https://www.medicuspharma.com

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Medicus Pharma Headlines

No Headlines